[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW524804B - Heterocyclic derivatives - Google Patents

Heterocyclic derivatives Download PDF

Info

Publication number
TW524804B
TW524804B TW089126096A TW89126096A TW524804B TW 524804 B TW524804 B TW 524804B TW 089126096 A TW089126096 A TW 089126096A TW 89126096 A TW89126096 A TW 89126096A TW 524804 B TW524804 B TW 524804B
Authority
TW
Taiwan
Prior art keywords
compound
mixture
present
ptc page
scope
Prior art date
Application number
TW089126096A
Other languages
English (en)
Chinese (zh)
Inventor
Alessandra Orlandi
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Application granted granted Critical
Publication of TW524804B publication Critical patent/TW524804B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
TW089126096A 1999-12-08 2000-12-07 Heterocyclic derivatives TW524804B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
TW524804B true TW524804B (en) 2003-03-21

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089126096A TW524804B (en) 1999-12-08 2000-12-07 Heterocyclic derivatives

Country Status (30)

Country Link
US (2) US6713491B2 (ko)
EP (1) EP1237886B1 (ko)
JP (1) JP4311901B2 (ko)
KR (1) KR100788579B1 (ko)
CN (1) CN1325488C (ko)
AR (1) AR030923A1 (ko)
AT (1) ATE323691T1 (ko)
AU (1) AU769232B2 (ko)
BR (1) BR0016235A (ko)
CA (1) CA2393303C (ko)
CO (1) CO5251474A1 (ko)
CY (1) CY1106105T1 (ko)
CZ (1) CZ301052B6 (ko)
DE (1) DE60027461T2 (ko)
DK (1) DK1237886T3 (ko)
ES (1) ES2257343T3 (ko)
GB (1) GB9929037D0 (ko)
HK (1) HK1047436B (ko)
HU (1) HUP0203650A3 (ko)
IL (2) IL150010A0 (ko)
MX (1) MXPA02005802A (ko)
MY (1) MY129892A (ko)
NO (1) NO323263B1 (ko)
PL (1) PL356713A1 (ko)
PT (1) PT1237886E (ko)
TN (1) TNSN00240A1 (ko)
TR (1) TR200201503T2 (ko)
TW (1) TW524804B (ko)
WO (1) WO2001042238A1 (ko)
ZA (1) ZA200204492B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096785A1 (ja) * 2003-04-25 2004-11-11 Nippon Chemiphar Co., Ltd. （２s，３s）－３－［［（１s）－１－イソブトキシメチル－３－メチルブチル］カルバモイル］オキシラン－２－カルボン酸の塩
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
PT3056492T (pt) 2004-10-08 2021-12-27 Abbvie Inc Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
EP1868581B1 (en) * 2005-04-11 2012-03-14 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
ES2574262T3 (es) * 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
AU708148B2 (en) 1995-09-29 1999-07-29 Glaxo Wellcome S.P.A. Tetrahydroquinolines as NMDA antagonists
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
KR100788579B1 (ko) 2007-12-26
CZ301052B6 (cs) 2009-10-21
AU769232B2 (en) 2004-01-22
US6943176B2 (en) 2005-09-13
ES2257343T3 (es) 2006-08-01
US20030008899A1 (en) 2003-01-09
EP1237886A1 (en) 2002-09-11
AU2006001A (en) 2001-06-18
HUP0203650A2 (hu) 2003-03-28
CN1407980A (zh) 2003-04-02
NO20022682L (no) 2002-07-17
PL356713A1 (en) 2004-06-28
EP1237886B1 (en) 2006-04-19
DK1237886T3 (da) 2006-08-14
JP2003516403A (ja) 2003-05-13
CY1106105T1 (el) 2011-06-08
CN1325488C (zh) 2007-07-11
HK1047436A1 (en) 2003-02-21
TNSN00240A1 (en) 2002-05-30
JP4311901B2 (ja) 2009-08-12
CZ20021981A3 (cs) 2003-01-15
CA2393303C (en) 2009-10-20
PT1237886E (pt) 2006-07-31
NO323263B1 (no) 2007-02-19
HUP0203650A3 (en) 2004-01-28
MY129892A (en) 2007-05-31
HK1047436B (zh) 2006-07-21
BR0016235A (pt) 2002-08-27
IL150010A0 (en) 2002-12-01
US20040162313A1 (en) 2004-08-19
CA2393303A1 (en) 2001-06-14
WO2001042238A1 (en) 2001-06-14
NO20022682D0 (no) 2002-06-06
ATE323691T1 (de) 2006-05-15
AR030923A1 (es) 2003-09-03
CO5251474A1 (es) 2003-02-28
DE60027461D1 (de) 2006-05-24
US6713491B2 (en) 2004-03-30
GB9929037D0 (en) 2000-02-02
ZA200204492B (en) 2004-06-30
KR20020086854A (ko) 2002-11-20
DE60027461T2 (de) 2006-09-28
IL150010A (en) 2009-09-01
MXPA02005802A (es) 2004-08-12
TR200201503T2 (tr) 2002-10-21

Similar Documents

Publication Publication Date Title
JPH07505407A (ja) インドール誘導体
EP0158532A2 (en) Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity.
EA023223B1 (ru) ПИРАЗОЛ[1,5-a]ПИРИМИДИНЫ ДЛЯ ПРОТИВОВИРУСНОГО ЛЕЧЕНИЯ
CA1309660C (en) Anxiolytic-n-(1-azabicyclo¬2.2.2|oct-3-yl) benzamides and thiobenzamides
TW201102385A (en) Substituted triazolopyridines and analogs thereof
KR20220101075A (ko) Il-17a 조절인자 및 이의 용도
AU592623B2 (en) (1-Azabicyclo (2.2.2) Oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
TW408117B (en) Use of N-substituted phenothiazines
TW524804B (en) Heterocyclic derivatives
WO2022052925A1 (zh) 一种洛普替尼晶型及其制备方法
EP0306345B1 (en) 2-alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
AU618027B2 (en) Anxiolytic-r-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides
AU597036B2 (en) Method of using 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamide-N-oxides to control emesis caused by anticancer drugs
EP0523013B1 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases
KR20000075907A (ko) (ｅ)-4,6-디클로로-3-(2-옥소-1-페닐피롤리딘-3-일리덴 메틸)-1ｈ-인돌-2-카르복실산의 결정질 수화 나트륨염
WO2004080965A1 (ja) ニューロペプチドff受容体拮抗剤
WO2022143897A1 (zh) A-失碳-5α雄甾烷化合物的多晶型物
WO2006029549A1 (fr) Composes de quinuclidine a groupe ammonium quaternaire, procede d'elaboration et utilisation comme agents de blocage de l'acetycholine
JPS60214784A (ja) 複素環式化合物
WO2009110519A1 (ja) 新規１－アミノカルボニルピペリジン誘導体
WO2000034274A1 (fr) Derives de la cyclohexylpiperidine
JPH05310735A (ja) 置換３−アミノキヌクリジンｐ物質拮抗剤
JPH03501725A (ja) 気管支疾患の治療用のチエノトリサイクレン
CZ314799A3 (cs) Krystalická hydratovaná sodná sůl kyseliny (E)-4,6-dichlor-3-(2-oxo-l-fenylpyrrolidin-3- ylidenmethyl)-lH-indol-2-karboxylové

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees